Last reviewed · How we verify
Placebo via ELLIPTA inhaler — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo via ELLIPTA inhaler (Placebo via ELLIPTA inhaler) — GlaxoSmithKline. Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo via ELLIPTA inhaler TARGET | Placebo via ELLIPTA inhaler | GlaxoSmithKline | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo via ELLIPTA inhaler CI watch — RSS
- Placebo via ELLIPTA inhaler CI watch — Atom
- Placebo via ELLIPTA inhaler CI watch — JSON
- Placebo via ELLIPTA inhaler alone — RSS
Cite this brief
Drug Landscape (2026). Placebo via ELLIPTA inhaler — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-via-ellipta-inhaler. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab